Home>>Signaling Pathways>> PROTAC>>ARD-2585

ARD-2585 Sale

目录号 : GC63704

ARD-2585 是有效的、具有口服活性的雄激素受体 (androgen receptor) 的PROTAC 降解剂。

ARD-2585 Chemical Structure

Cas No.:2757422-79-8

规格 价格 库存 购买数量
5 mg
¥8,640.00
现货
10 mg
¥13,950.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

ARD-2585 is an exceptionally potent and orally active PROTAC degrader of androgen receptor[1].

ARD-2585 achieves DC50 values of 0.04-0.1 nM in the VCaP cell line with AR gene amplification and in the LNCaP cell line carrying an AR mutation[1].ARD-2585 (100 nM) is effective in reducing the AR protein level at the 3 and 24 h time-points by 78% (p 0.05)[1].

[1]. Weiguo Xiang. et al. Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. J Med Chem. 2021 Sep 23;64(18):13487-13509.

Chemical Properties

Cas No. 2757422-79-8 SDF
分子式 C41H43ClN8O5 分子量 763.28
溶解度 DMSO : 85 mg/mL (111.36 mM; Need ultrasonic) 储存条件 Store at -20°C, sealed storage, away from moisture and light
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.3101 mL 6.5507 mL 13.1014 mL
5 mM 0.262 mL 1.3101 mL 2.6203 mL
10 mM 0.131 mL 0.6551 mL 1.3101 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer

J Med Chem 2021 Sep 23;64(18):13487-13509.PMID:34473519DOI:PMC8855934

We report herein the discovery of exceptionally potent and orally bioavailable PROTAC AR degraders with ARD-2585 being the most promising compound. ARD-2585 achieves DC50 values of ≤0.1 nM in the VCaP cell line with AR gene amplification and in the LNCaP cell line carrying an AR mutation. It potently inhibits cell growth with IC50 values of 1.5 and 16.2 nM in the VCaP and LNCaP cell lines, respectively, and achieves excellent pharmacokinetics and 51% of oral bioavailability in mice. It is more efficacious than enzalutamide in inhibition of VCaP tumor growth and does not cause any sign of toxicity in mice. ARD-2585 is a promising AR degrader for extensive investigations for the treatment of advanced prostate cancer.